Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High-molecular-weight formalinized allergoids are chemically modified allergen extracts created by treating natural allergens with formaldehyde (formalin), resulting in covalent cross-linking and polymerization of the proteins. This process produces large molecular weight complexes (typically above 85,000 Da and up to 10^5–10^6 Da) that retain immunogenicity but have significantly reduced IgE-mediated allergenicity. The modification allows for safer administration of higher doses during allergen immunotherapy (AIT), reducing the risk of systemic allergic reactions while maintaining or enhancing the ability to induce immune tolerance through increased production of blocking antibodies and regulatory T cell responses. These preparations are used primarily in subcutaneous or sublingual immunotherapy for allergic diseases such as allergic rhinoconjunctivitis and grass pollen allergy[3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on high-molecular-weight formalinized allergoid.